[go: up one dir, main page]

PE20060317A1 - Derivados de xantina como agonistas selectivos del receptor de acido nicotinico - Google Patents

Derivados de xantina como agonistas selectivos del receptor de acido nicotinico

Info

Publication number
PE20060317A1
PE20060317A1 PE2005000170A PE2005000170A PE20060317A1 PE 20060317 A1 PE20060317 A1 PE 20060317A1 PE 2005000170 A PE2005000170 A PE 2005000170A PE 2005000170 A PE2005000170 A PE 2005000170A PE 20060317 A1 PE20060317 A1 PE 20060317A1
Authority
PE
Peru
Prior art keywords
nicotinic acid
acid receptor
selective agonists
alkyl
diona
Prior art date
Application number
PE2005000170A
Other languages
English (en)
Inventor
Ivan Leo Pinto
Shahzad Sharooq Rahman
Neville Hubert Nicholson
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0403282A external-priority patent/GB0403282D0/en
Priority claimed from GB0423562A external-priority patent/GB0423562D0/en
Priority claimed from GB0428375A external-priority patent/GB0428375D0/en
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of PE20060317A1 publication Critical patent/PE20060317A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE R1 H, ALQUILO C1-C4 SUSTITUIDO O NO POR CN, CF3; R2 ES ALQUILO C3-C10, ALQUILO C1-C10 SUSTITUIDO CON 1 O MAS GRUPOS DE F, CN, ENTRE OTROS; R3 ES HALOGENO, CN. SON COMPUESTOS PREFERIDOS: 8-CLORO-3-(4-PENTEN-1-IL)-3,7-DIHIDRO-1H-PURINA-2,6-DIONA; (8-CLORO-2,6-DIOXO-1,2,6,7-TETRAHIDRO-3H-PRIN-3-IL)ACETONITRILO; 8-CLORO-3-(4,4,4-TRIFLUOROBUTIL)-3,7-DIHIDRO-1H-PURINA-2,6-DIONA; ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON AGONISTAS SELECTIVOS DEL RECEPTOR DE ACIDO NICOTINICO HM74A UTILES EN ENFERMEDADES DEL METABOLISMO DE LIPIDOS, INSUFICIENCIA CARDIACA, ARTERIOSCLEROSIS, TROMBOSIS, ANGINA, ENTRE OTROS
PE2005000170A 2004-02-14 2005-02-11 Derivados de xantina como agonistas selectivos del receptor de acido nicotinico PE20060317A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0403282A GB0403282D0 (en) 2004-02-14 2004-02-14 Chemical compounds
GB0423562A GB0423562D0 (en) 2004-10-22 2004-10-22 Novel compounds
GB0428375A GB0428375D0 (en) 2004-12-24 2004-12-24 Novel compounds

Publications (1)

Publication Number Publication Date
PE20060317A1 true PE20060317A1 (es) 2006-06-22

Family

ID=34864831

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000170A PE20060317A1 (es) 2004-02-14 2005-02-11 Derivados de xantina como agonistas selectivos del receptor de acido nicotinico

Country Status (25)

Country Link
US (5) US7713982B2 (es)
EP (1) EP1781657B1 (es)
JP (2) JP5001012B2 (es)
KR (1) KR101100601B1 (es)
CN (2) CN101863888B (es)
AR (1) AR047669A1 (es)
AU (1) AU2005212816C1 (es)
BR (1) BRPI0507604A (es)
CA (1) CA2556073C (es)
CY (1) CY1114022T1 (es)
DK (1) DK1781657T3 (es)
ES (1) ES2406732T3 (es)
HR (1) HRP20130406T1 (es)
IL (1) IL177051A (es)
MA (1) MA28357A1 (es)
MY (1) MY148937A (es)
NO (1) NO337281B1 (es)
NZ (1) NZ548496A (es)
PE (1) PE20060317A1 (es)
PL (1) PL1781657T3 (es)
PT (1) PT1781657E (es)
SG (1) SG157242A1 (es)
SI (1) SI1781657T1 (es)
TW (1) TWI350289B (es)
WO (1) WO2005077950A2 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034610A1 (en) * 1999-11-12 2001-05-17 Biogen, Inc. Polycycloalkylpurines as adenosine receptor antagonists
AR039385A1 (es) 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
US7094572B2 (en) 2003-03-14 2006-08-22 Bristol-Myers Squibb Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74
PE20050483A1 (es) 2003-10-31 2005-08-25 Arena Pharm Inc Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas
BRPI0507604A (pt) * 2004-02-14 2007-07-03 Smithkline Beecham Corp medicamentos com atividade de receptor hm74a
SG163577A1 (en) 2004-12-03 2010-08-30 Schering Corp Substituted piperazines as cb1 antagonists
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
CA2608405A1 (en) 2005-05-17 2006-11-23 Schering Corporation Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US7750015B2 (en) 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
AU2006259137B2 (en) * 2005-06-14 2010-04-01 F. Hoffmann-La Roche Ag Anthranilic acid derivatives
CN101208082A (zh) 2005-06-28 2008-06-25 默克公司 烟酸受体激动剂、含有所述化合物的组合物和治疗方法
BRPI0614270A2 (pt) * 2005-08-10 2011-03-22 Smithkline Beecham Corp derivados xantina como seletivos agonistas de ha74a
AR059056A1 (es) 2006-01-20 2008-03-12 Schering Corp Heterociclos compo agonistas del receptor de acido nicotinico para el tratamiento de la dislipidemia
ES2344086T3 (es) 2006-05-23 2010-08-17 F. Hoffmann-La Roche Ag Derivados de piridopirimidinona.
TW200804383A (en) 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
EP2049544B9 (en) 2006-06-23 2011-07-20 Incyte Corporation Purinone derivatives as hm74a agonists
US7511050B2 (en) * 2006-06-23 2009-03-31 Incyte Corporation Purinone derivatives as HM74A agonists
BRPI0808721A2 (pt) * 2007-03-23 2014-08-12 Hoffmann La Roche Compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que são moduladas por agonistas hm74a e uso dos compostos
DK2370440T3 (en) * 2008-12-08 2014-12-08 Glaxosmithkline Llc 8-Chloro-3-pentyl-3,7-dihydro-1H-purine-2,6-dion2-amino-2- (hydroxymethyl) -1,3-propandiolanhydrat for the treatment of diseases
EP2379562A1 (en) 2008-12-16 2011-10-26 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
EP2379547A1 (en) 2008-12-16 2011-10-26 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
CN102276610B (zh) * 2011-05-04 2013-01-09 北京工业大学 N7-鸟嘌呤烷化物的制备方法
CN103360394B (zh) * 2013-07-29 2015-07-22 上海万巷制药有限公司 8-氯茶碱的制备方法
SMT202100359T1 (it) * 2015-01-30 2021-07-12 Shanton Pharma Pte Ltd Prevenzione o trattamento della malattia dell'acido urico o della gotta
CN104892610B (zh) * 2015-05-27 2016-08-24 福建师范大学 一种8-酯基咖啡因衍生物的制备方法
CN105622610A (zh) * 2016-03-28 2016-06-01 浙江诚意药业股份有限公司 一种黄嘌呤化合物的制备方法
EP3490579B1 (en) 2016-07-27 2025-09-10 Hartis-Pharma SA Therapeutic combinations to treat red blood cell disorders
CN106632061B (zh) * 2016-11-23 2020-07-24 上海皓元医药股份有限公司 一种1-(4-苯基-1-烷基-1h-咪唑-2-基)乙酮及其衍生物的合成方法
AU2018208422B2 (en) 2017-01-10 2021-11-11 Bayer Aktiengesellschaft Heterocyclene derivatives as pest control agents
JP2022549807A (ja) * 2019-09-25 2022-11-29 ゴールドフィンチ バイオ，インク． キサンチンｃｂ１阻害物質
CN112724141A (zh) * 2021-01-21 2021-04-30 南京艾美斐生物医药科技有限公司 一种gpr109a蛋白受体抑制剂及其制备和应用
CN113262882B (zh) * 2021-07-21 2021-09-17 北京矿冶研究总院 阳离子捕收剂、制备方法及在磷矿反浮选中的应用
AU2024229006A1 (en) * 2023-02-27 2025-09-18 Shanton Pharma Pte. Ltd. Crystal form of 8-chloro-3-pentyl-3,7-dihydro-1h-purin-2,6-dione compound and preparation method therefor

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2797220A (en) * 1954-12-02 1957-06-25 Univ Michigan Substituted paraxanthines
US4847377A (en) * 1985-05-13 1989-07-11 Schering Corporation Substituted-2,3-dihydro-6-substituted-pyrimido[2,1-F]-purine-4,8(1H,9H)-diones
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
NZ240644A (en) 1990-11-21 1994-08-26 Smithkline Beecham Corp Use of xanthine derivatives to inhibit the production of tumour necrosis factor (tnf)
WO1993016699A1 (en) * 1992-02-21 1993-09-02 Smithkline Beecham Corporation Tnf inhibitors
DE69332634T2 (de) 1992-03-04 2003-05-08 Cell Therapeutics, Inc. Enantiomere hydroxylierte xanthinverbindungen
US6693105B1 (en) 1992-11-16 2004-02-17 Cell Therapeutics, Inc. Hydroxyl-containing compounds
US6469017B1 (en) 1998-01-16 2002-10-22 Cell Therapeutics, Inc. Method of inhibiting interleukin-12 signaling
US5780476A (en) 1992-11-16 1998-07-14 Cell Therapeutics, Inc. Hydroxyl-containing xanthine compounds
US5473070A (en) 1992-11-16 1995-12-05 Cell Therapeutics, Inc. Substituted long chain alcohol xanthine compounds
IL109161A0 (en) 1993-03-31 1994-06-24 Cell Therapeutics Inc Amino alcohol derivatives, methods for the preparation thereof, and pharmaceutical compositions containing the same
US5670506A (en) 1993-04-05 1997-09-23 Cell Therapeutics, Inc. Halogen, isothiocyanate or azide substituted xanthines
AU6702894A (en) 1993-04-09 1994-11-08 Cell Therapeutics, Inc. Ring-substituted cell signaling inhibitors
AU1868195A (en) 1994-01-28 1995-08-15 Cell Therapeutics, Inc. Cell signaling inhibitors
US6780865B1 (en) 1994-02-18 2004-08-24 Cell Therapeutics, Inc. Compounds having selective hydrolytic potentials
US6103730A (en) 1994-03-24 2000-08-15 Cell Therapeutics, Inc. Amine substituted compounds
US6878715B1 (en) 1994-02-18 2005-04-12 Cell Therapeutics, Inc. Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
CA2183562A1 (en) 1994-02-18 1995-08-24 J. Peter Klein Intracellular signalling mediators
US5807861A (en) 1994-03-24 1998-09-15 Cell Therapeutics, Inc. Amine substituted xanthinyl compounds
US5801182A (en) 1994-03-24 1998-09-01 Cell Therapeutics, Inc. Amine substituted compounds
US6323201B1 (en) 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
AR015966A1 (es) 1997-10-17 2001-05-30 Smithkline Beecham Corp Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
EP1171442B1 (en) 1999-04-09 2005-12-07 Cell Therapeutics, Inc. Xanthine derivatives and analogs as cell signalling inhibitors
US20030207901A1 (en) 1999-07-27 2003-11-06 Cell Therapeutics, Inc. Hydroxyl-containing compounds
NZ517546A (en) * 1999-08-31 2003-10-31 Univ Vanderbilt Selective antagonists of A2B adenosine receptors
EP1305328A2 (en) * 2000-07-21 2003-05-02 Mark B. Lyles Materials and methods for binding nucleic acids to surfaces
FR2812482B1 (fr) * 2000-07-28 2003-01-24 Inside Technologies Dispositif electronique portable comprenant plusieurs circuits integres sans contact
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
AU2002210521A1 (en) * 2000-09-19 2002-04-02 Novimmune S.A. Use of statins (HMG-CoA reductase inhibitors) for the preparation of medicament as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent
IL157471A0 (en) 2001-02-24 2004-03-28 Boehringer Ingelheim Pharma Xanthine derivatives, production and use thereof as a medicament
AU2002242910A1 (en) * 2001-04-11 2002-10-28 Glaxo Group Limited Medicaments which are modulators of hm74 and/or hm74a activity
BRPI0507604A (pt) * 2004-02-14 2007-07-03 Smithkline Beecham Corp medicamentos com atividade de receptor hm74a
WO2006045564A1 (en) 2004-10-22 2006-05-04 Smithkline Beecham Corporation Xanthine derivatives with hm74a receptor activity
US20090209561A1 (en) 2004-10-22 2009-08-20 Richard Jonathan Daniel Hatley Xanthine Derivatives with HM74A Receptor Activity
BRPI0614270A2 (pt) 2005-08-10 2011-03-22 Smithkline Beecham Corp derivados xantina como seletivos agonistas de ha74a
EP1939197A1 (en) * 2006-12-22 2008-07-02 Schwarz Pharma Ag 8-ethinylxanthine derivatives as selective A2A receptor antagonists
DK2370440T3 (en) * 2008-12-08 2014-12-08 Glaxosmithkline Llc 8-Chloro-3-pentyl-3,7-dihydro-1H-purine-2,6-dion2-amino-2- (hydroxymethyl) -1,3-propandiolanhydrat for the treatment of diseases
US20110065676A1 (en) * 2009-06-24 2011-03-17 Schering Corporation Combination therapies comprising par1 antagonists with nar agonists

Also Published As

Publication number Publication date
CN101863888A (zh) 2010-10-20
HK1104530A1 (en) 2008-01-18
US7713982B2 (en) 2010-05-11
WO2005077950A3 (en) 2007-04-19
AU2005212816B2 (en) 2009-07-23
BRPI0507604A (pt) 2007-07-03
CN101103030A (zh) 2008-01-09
JP5020848B2 (ja) 2012-09-05
TW200536537A (en) 2005-11-16
IL177051A0 (en) 2006-12-10
TWI350289B (en) 2011-10-11
US20100160354A1 (en) 2010-06-24
AU2005212816A1 (en) 2005-08-25
SI1781657T1 (sl) 2013-07-31
CY1114022T1 (el) 2016-07-27
KR20060126772A (ko) 2006-12-08
NO20064151L (no) 2006-11-06
IL177051A (en) 2013-01-31
EP1781657B1 (en) 2013-03-27
KR101100601B1 (ko) 2011-12-29
MA28357A1 (fr) 2006-12-01
MY148937A (en) 2013-06-14
EP1781657A2 (en) 2007-05-09
JP2007522176A (ja) 2007-08-09
JP5001012B2 (ja) 2012-08-15
US8394808B2 (en) 2013-03-12
CN101103030B (zh) 2010-10-13
CA2556073C (en) 2012-01-10
NO337281B1 (no) 2016-02-29
US20150080418A1 (en) 2015-03-19
US20070135456A1 (en) 2007-06-14
DK1781657T3 (da) 2013-06-10
US20130150383A1 (en) 2013-06-13
JP2008120831A (ja) 2008-05-29
PT1781657E (pt) 2013-05-23
CN101863888B (zh) 2012-07-18
PL1781657T3 (pl) 2013-08-30
SG157242A1 (en) 2009-12-29
AR047669A1 (es) 2006-02-01
AU2005212816C1 (en) 2010-03-04
ES2406732T3 (es) 2013-06-07
US20100010021A1 (en) 2010-01-14
US8268839B2 (en) 2012-09-18
CA2556073A1 (en) 2005-08-25
NZ548496A (en) 2010-02-26
WO2005077950A2 (en) 2005-08-25
HRP20130406T1 (hr) 2013-06-30

Similar Documents

Publication Publication Date Title
PE20060317A1 (es) Derivados de xantina como agonistas selectivos del receptor de acido nicotinico
PE20080251A1 (es) Usos de inhibidores de dpp iv
Innocenti et al. Design of potent and selective hybrid inhibitors of the mitotic kinase Nek2: structure–activity relationship, structural biology, and cellular activity
PE20061442A1 (es) Heterociclicos como agonistas del receptor de acido nicotinico para el tratamiento de dislipidemia
EA200500881A1 (ru) N-арилсульфонил-3-замещенные индолы, обладающие афинностью к серотониновому рецептору, способ их получения и содержащая их фармацевтическая композиция
PE20140630A1 (es) Derivados de acido 3-fenilpropionico ramificados y su uso
CY1111757T1 (el) Παραγωγα ξανθινης ως εκλεκτικοι αναστολεις ημ74α
PE20130402A1 (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
PE20081800A1 (es) NUEVOS DERIVADOS DE 3-([1,2,4]TRIAZOLO[4,3-a]PIRIDIN-7-IL)BENZAMIDA
PE20080186A1 (es) Derivados 4,6-disustituidos de 2-metoxi-6-etilamino-pirimidina como antagonistas del receptor de prostaglandina d2
AR072557A1 (es) Proceso para preparar composiciones de medicamentos que contienen dabigatran
EA201100079A1 (ru) Производные триазоло[4,5-d]пирамидина и их применение в качестве антагонистов пуринового рецептора
CY1114092T1 (el) Σπειρο υποκατεστημενες ενωσεις ως αναστολεις αγγειογενεσης
PE20080421A1 (es) Derivados de 5,6-bisaril-2-piridin-carboxamida, su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de urotensina ii
NO20085257L (no) Purinonderivater som HM74a-agonister
MXPA05011710A (es) Derivados de pirimidina con actividad de crf.
EA200101107A1 (ru) Пуриновые производные
PE20140250A1 (es) Derivados de piperidina puenteada
UY27965A1 (es) Derivados heterocíclicos
PE20081806A1 (es) Imidazo- y triazolopirimidinas sustituidas
PE20070706A1 (es) Nuevos derivados imidazopiridina como antagonistas de adenosina a2b
CY1105982T1 (el) Συνδετες υποδοχεων γλυκοκορτικοειδων για την θepαπεια των μεταβολικων διαταραχων
PE1998A1 (es) DERIVADOS DE BENZO [g] QUINOLINA
PE20140968A1 (es) Derivados de benzamida sustituida
ECSP077404A (es) Derivados de purina para usarse como agonistas de receptores a-2a de adenosina

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed